Bridget Koontz, MD,
Open to Accrual
Compare conventional radiological progression-freesurvival (rPFS) for positron emission tomography (PET)-detected, biochemicallyrecurrent, oligometastatic, castration-sensitive prostate cancer patients treatedwith SABR plus placebo vs. SABR plus relugolix.
Pathologically proven diagnosis of prostate adenocarcinoma and are recurrent oligometastatic.
NRG-GU011 The Promethean Study Overview by Bridget Koontz, MD
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.